

CONTENTS

LIST OF FIGURES

LIST OF TABLES

SUMMARY

<u>CHAPTER 1</u>		<u>page</u>
GENERAL INTRODUCTION		
1.	General introduction	1
1.1	Nuclear medicine and radioactivity	1
1.1.1	Radionuclides used for diagnostic nuclear medicine	3
1.2	Chemistry of technetium	6
1.3	Nuclear and radiochemistry of technetium	9
1.4	Production of technetium-99m	10
1.4.1	Methods of technetium-99m separation	10
1.5	Labelling with technetium-99m	13
1.5.1	Labelling methods with technetium-99m	15
1.5.1.1	Direct labelling method	15
1.5.1.2	Indirect labelling method	16
1.5.1.3	Labelling with bifunctional chelating agents	17
1.6	Groups ^{99m}Tc -Radiopharmaceuticals	18
1.6.1	Classes of ^{99m}Tc -radiopharmaceuticals	19
1.6.1.1	Pertechnetate ion ($^{99m}\text{TcO}_4^-$)	19
1.6.1.2	^{99m}Tc -Labelled colloids and particulates	19
1.6.1.3	^{99m}Tc -Chelates for skeletal imaging	20
1.6.1.4	^{99m}Tc -Chelates for renal imaging	21
1.6.1.5	^{99m}Tc -Chelates for hepatobiliary imaging	22
1.6.1.6	^{99m}Tc -Chelates for myocardial imaging	23
1.6.1.7	^{99m}Tc -Chelates for brain imaging	24
1.6.1.8	^{99m}Tc -Complexes for lung imaging	25
1.7	Radionuclides used for therapeutic nuclear medicine	26
1.8	Freeze drying	29
1.9	Kit preparation	30
1.10	Quality control radiopharmaceuticals	32

CHAPTER 2

SYNTHESIS OF SOME PHOSPHONATE DERIVATIVES

2.	Synthesis of some phosphonate derivatives	33
2.1	Introduction	33
2.2	Experimental	37
2.2.1	Chemicals and reagents	37
2.2.2	Solvents	38
2.2.3	Equipment	38
2.2.4	Methods	39
2.2.4.1	Preparation of 1-Mercaptoethylidene-1,1-diphosphonic acid (MEDPA, 1) and its disodium salt (MEDP, 2)	39
2.2.4.1.1	Preparation of 1-Mercaptoethylidene-1,1-diphosphonic acid, (MEDPA, 1)	39
2.2.4.1.2	Preparation of 1-Mercaptoethylidene-1,1-disodium phosphonate, (MEDP, 2)	40
2.2.4.2	Preparation of 1-Hydroxypropylidene-1,1-diphosphonic acid (HPDPA, 1) and its disodium salt (MEDP, 2)	40
2.2.4.2.1	Preparation of 1-Hydroxypropylidene-1,1- diphosphonic acid (HPDPA, 1)	40
2.2.4.2.2	Preparation of 1-Hydroxypropylidene-1,1- disodium phosphonate, (HPDP, 2)	
2.3	Results and discussion	42
2.3.1	Synthesis and characterization of 1-Mercaptoethylidene-1,1-disodium phosphonate (MEDP, 2)	42
2.3.1.1	Synthesis of MEDP	42
2.3.1.2	Characterization of both MEDPA and MEDP	42
2.3.1.2.1	Characterization of MEDPA	42
2.3.1.2.2	Characterization of MEDP	45
2.3.2	Synthesis and characterization of 1-Hydroxypropylidene-1,1-disodium phosphonate (HPDP, 2)	50
2.3.2.1	Synthesis of HPDP	50
2.3.2.2	Characterization of both HPDPA and HPDP	52
2.3.2.2.1	Characterization of HPDPA	52
2.3.2.2.2	Characterization of HPDP	53

CHAPTER 3

TECHNETIUM-99m-PHOSPHONATE COMPLEXES: PREPARATION AND BIOLOGICAL DISTRIBUTION

3.	^{99m} Tc-phosphonate complexes	58
3.1	Introduction	58
3.2	Experimental	60
3.2.1	Materials	60
3.2.1.1	Chemicals	60
3.2.1.2	Solvents	61
3.2.2	Equipment	61
3.2.3	Animals	61
3.2.4	Radioactive material	62
3.2.5	Methods	62
3.2.5.1	Preparation of stock solution of tin(II) content	62
3.2.6	Kit Preparation and labelling	62
3.2.7	Analysis of ^{99m} Tc-phosphonate complexes by using radiochromatographic techniques	63
3.2.7.1	Analysis of ^{99m} Tc-phosphonate complexes by using PC technique	63
3.2.7.2	Analysis of ^{99m} Tc-phosphonate complexes by using TLC-SG technique	64
3.2.7.3	Analysis of ^{99m} Tc-phosphonate complexes by using gel chromatography column elution (GCE) technique	64
3.2.7.4	Analysis of ^{99m} Tc-phosphonate complexes by using gel chromatography column scanning (GCS) technique	65
3.2.8	Study of the factors affecting the percent labelling yield of ^{99m} Tc-phosphonate complexes	65
3.2.8.1	Effect of reaction time	66
3.2.8.2	Effect of phosphonate derivative content	66
3.2.8.3	Effect of tin (II) content	66
3.2.8.4	Effect of pH of the reaction medium	66
3.2.9	In-vitro stability of ^{99m} Tc-phosphonate complexes	67
3.2.10	Biodistribution study in mice	67
3.3	Results and discussion	68
3.3.1	Study of the factors affecting the percent labelling yield	69
3.3.1.1	Effect of reaction time	69

3.3.1.2	Effect of ligand content	69
3.3.1.3	Effect of tin (II) content	71
3.3.1.4	Effect of pH of the reaction medium	74
3.3.2	In-vitro stability of ^{99m}Tc -phosphonate complexes	76
3.3.3	Biological distribution study	79

LIST OF TABLES

<u>Table</u>	<u>Page</u>
(1) Routine methods of production of some commonly used γ -ray emitters	4
(2) Some of the fundamental data of technetium	6
(3) Principal radionuclides of technetium	11
(4) Essential groups present in many chelating agents used for ^{99m}Tc -complexes	14
(5) Physical properties of some therapeutic radionuclides and their production methods	27
(6) Some therapeutic radionuclides and their uses in nuclear medicine	28
(7) Physical properties of some α -emitters	29
(8) Effect of HPDP content on the percent labelling yield of ^{99m}Tc -HPDP complex	70
(9) Effect of MEDP content on the percent labelling yield of ^{99m}Tc -MEDP complex	71
(10) Effect of Sn(II) content on the percent labelling yield of ^{99m}Tc -HPDP complex	73
(11) Effect of Sn(II) content on the percent labelling yield of ^{99m}Tc -MEDP complex	74
(12) Effect of the pH value on the percent labelling yield of the ^{99m}Tc -HPDP	75
(13) Effect of the pH value on the percent labelling yield of the ^{99m}Tc -MEDP	76
(14) The <i>in-vitro</i> stability of ^{99m}Tc -HPDP complexes as a function of the time elapsed after labelling	77
(15) The <i>in-vitro</i> stability of ^{99m}Tc -MEDP complexes as a function of the time elapsed after labelling	78
(16) Biological distribution of ^{99m}Tc -HPDP complex in mice as a function of time	81
(17) Biological distribution of ^{99m}Tc -MEDP complex in mice as a function of time	82

LIST OF FIGURES

<u>Figure</u>	<u>Page</u>
(1) Selected relationships of technetium chemistry	8
(2) Decay scheme of technetium-99m	9
(3) Decay scheme of ^{99}Mo - $^{99\text{m}}\text{Tc}$ radionuclides	10
(4) Structures of some common bifunctional chelating agents	18
(5) Structures of some pharmaceuticals used for skeletal imaging after labelling with $^{99\text{m}}\text{Tc}$	20
(6) Structures of some radiopharmaceuticals used for kidney imaging and renal function study after labelling with $^{99\text{m}}\text{Tc}$	22
(7) Structures of IDA complexes suggested as hepatobiliary imaging agent after labelling with $^{99\text{m}}\text{Tc}$	23
(8) Structure of some pharmaceuticals used for myocardial perfusion imaging	24
(9) Structure of some $^{99\text{m}}\text{Tc}$ -radiopharmaceuticals used for brain perfusion imaging	25
(10) Scheme for the production of kits for the preparation of nuclear medicine	31
(11) Compounds of HEDPA and HEDP	33
(12) Structure of compounds of NTMP & DTPMP	36
(13) Preparation reaction of MEDPA	42
(14) Equivalence points of pH values for MEDPA	43
(15) Tribasic titration curve of MEDPA	44
(16) IR spectrum of MEDP	47
(17) ^{31}P spectrum of MEDP	48
(18) ^1H -NMR spectrum of MEDP	49
(19) Preparation reaction of HPDPA	50
(20) Tribasic titration curve of HPDPA	51
(21) Equivalence points of pH values for HPDPA	52
(22) IR spectrum of HPDP	55
(23) ^{31}P spectrum of HPDP	56
(24) ^1H -NMR spectrum of HPDP	57
(25) ^{13}C -NMR spectrum of HPDP	58